MedTrace Logo

Non-Interventional Open Label Prospective Comparative Observational Study Of Evaluation Of Compliance In The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Of Acute Bacterial Maxillary Sinusitis

NCT01032174 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 123

Last updated 2012-04-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare compliance between patients with Acute Bacterial Sinusitis (ABS) treated with Azithromycin SR 2.0 g single dose orally and those treated with Amoxiclav - 1000 mg twice daily 10 days for the empiric treatment of ABS in outpatient clinic practice.

Conditions

  • Maxillary Sinusitis

Interventions

DRUG

Azithromycin SR

Azithromycin SR, 2.0 g by mouth (PO) x 1

DRUG

Amoxiclav 1000 mg

Amoxiclav 1000 mg x twice daily, 10 days

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-03-31
Completion
2011-03-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01032174 on ClinicalTrials.gov